211 related articles for article (PubMed ID: 15834946)
1. Arrested spread of vesicular stomatitis virus infections in vitro depends on interferon-mediated antiviral activity.
Lam V; Duca KA; Yin J
Biotechnol Bioeng; 2005 Jun; 90(7):793-804. PubMed ID: 15834946
[TBL] [Abstract][Full Text] [Related]
2. Quantifying viral propagation in vitro: toward a method for characterization of complex phenotypes.
Duca KA; Lam V; Keren I; Endler EE; Letchworth GJ; Novella IS; Yin J
Biotechnol Prog; 2001; 17(6):1156-65. PubMed ID: 11735454
[TBL] [Abstract][Full Text] [Related]
3. Matrix protein of VSV New Jersey serotype containing methionine to arginine substitutions at positions 48 and 51 allows near-normal host cell gene expression.
Kim GN; Kang CY
Virology; 2007 Jan; 357(1):41-53. PubMed ID: 16962155
[TBL] [Abstract][Full Text] [Related]
4. Superantigen-activated T cells redirected by a bispecific antibody inhibit vesicular stomatitis virus replication in vitro and in vivo.
Fernandez-Sesma A; Peluso RW; Bai X; Schulman JL; Levy DE; Moran TM
J Immunol; 1998 Feb; 160(4):1841-9. PubMed ID: 9469445
[TBL] [Abstract][Full Text] [Related]
5. Matrix protein mediated shutdown of host cell metabolism limits vesicular stomatitis virus-induced interferon-alpha responses to plasmacytoid dendritic cells.
Waibler Z; Detje CN; Bell JC; Kalinke U
Immunobiology; 2007; 212(9-10):887-94. PubMed ID: 18086387
[TBL] [Abstract][Full Text] [Related]
6. Vesicular stomatitis.
Letchworth GJ; Rodriguez LL; Del cbarrera J
Vet J; 1999 May; 157(3):239-60. PubMed ID: 10328837
[TBL] [Abstract][Full Text] [Related]
7. Individual differentiation of innate antiviral immunity in humans; the role of endogenous interferons and tumor necrosis factor in the immunity of leukocytes.
Orzechowska B; Antoszków Z; Błach-Olszewska Z
Arch Immunol Ther Exp (Warsz); 2003; 51(1):51-60. PubMed ID: 12691304
[TBL] [Abstract][Full Text] [Related]
8. Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity.
Hoffmann M; Wu YJ; Gerber M; Berger-Rentsch M; Heimrich B; Schwemmle M; Zimmer G
J Gen Virol; 2010 Nov; 91(Pt 11):2782-93. PubMed ID: 20631091
[TBL] [Abstract][Full Text] [Related]
9. VSV replication in neurons is inhibited by type I IFN at multiple stages of infection.
Trottier MD; Palian BM; Reiss CS
Virology; 2005 Mar; 333(2):215-25. PubMed ID: 15721356
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
Ahmed M; Cramer SD; Lyles DS
Virology; 2004 Dec; 330(1):34-49. PubMed ID: 15527832
[TBL] [Abstract][Full Text] [Related]
11. The specific and essential role of MAVS in antiviral innate immune responses.
Sun Q; Sun L; Liu HH; Chen X; Seth RB; Forman J; Chen ZJ
Immunity; 2006 May; 24(5):633-42. PubMed ID: 16713980
[TBL] [Abstract][Full Text] [Related]
12. Progression of a vesicular stomatitis virus infection in primary lymphocytes is restricted at multiple levels during B cell activation.
Schmidt MR; Gravel KA; Woodland RT
J Immunol; 1995 Sep; 155(5):2533-44. PubMed ID: 7650383
[TBL] [Abstract][Full Text] [Related]
13. Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection.
Sharif-Askari E; Nakhaei P; Oliere S; Tumilasci V; Hernandez E; Wilkinson P; Lin R; Bell J; Hiscott J
Virology; 2007 Aug; 365(1):20-33. PubMed ID: 17451770
[TBL] [Abstract][Full Text] [Related]
14. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses.
Fink K; Lang KS; Manjarrez-Orduno N; Junt T; Senn BM; Holdener M; Akira S; Zinkernagel RM; Hengartner H
Eur J Immunol; 2006 Aug; 36(8):2094-105. PubMed ID: 16810635
[TBL] [Abstract][Full Text] [Related]
15. The biological effects of five feline IFN-alpha subtypes.
Baldwin SL; Powell TD; Sellins KS; Radecki SV; Cohen JJ; Milhausen MJ
Vet Immunol Immunopathol; 2004 Jun; 99(3-4):153-67. PubMed ID: 15135982
[TBL] [Abstract][Full Text] [Related]
16. Expression of lymphotoxin beta governs immunity at two distinct levels.
Junt T; Tumanov AV; Harris N; Heikenwalder M; Zeller N; Kuprash DV; Aguzzi A; Ludewig B; Nedospasov SA; Zinkernagel RM
Eur J Immunol; 2006 Aug; 36(8):2061-75. PubMed ID: 16841297
[TBL] [Abstract][Full Text] [Related]
17. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
18. Using G-deleted vesicular stomatitis virus to probe the innate anti-viral response.
Lai F; Kazdhan N; Lichty BD
J Virol Methods; 2008 Nov; 153(2):276-9. PubMed ID: 18692525
[TBL] [Abstract][Full Text] [Related]
19. Impact of macrophage and dendritic cell subset elimination on antiviral immunity, viral clearance and production of type 1 interferon.
Ciavarra RP; Taylor L; Greene AR; Yousefieh N; Horeth D; van Rooijen N; Steel C; Gregory B; Birkenbach M; Sekellick M
Virology; 2005 Nov; 342(2):177-89. PubMed ID: 16143360
[TBL] [Abstract][Full Text] [Related]
20. MyD88 protects from lethal encephalitis during infection with vesicular stomatitis virus.
Lang KS; Navarini AA; Recher M; Lang PA; Heikenwalder M; Stecher B; Bergthaler A; Odermatt B; Akira S; Honda K; Hengartner H; Zinkernagel RM
Eur J Immunol; 2007 Sep; 37(9):2434-40. PubMed ID: 17668900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
